LH
Labcorp
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 2
consensus rating "Strong Buy"
Low Cash Short-term Debt Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About LH
Labcorp Holdings Inc.
A leading global life sciences company that provides clinical testing services for healthcare industry
Healthcare Providers and Services
Invalid Date
04/24/1991
New York Stock Exchange
70000
12-31
Common stock
358 South Main Street, Burlington, North Carolina, 27215
--
Labcorp Holdings Inc., a Delaware corporation, was founded in 1971. The Company is a leading global life sciences company that is deeply integrated in guiding patient care. The Company provides comprehensive clinical laboratory and end-to-end drug development services through its LabCorp Diagnostics (LCD) and Covance Drug Development (CDD) divisions. LabCorp is positioned at the fusion of research and care delivery for more precise and personalized healthcare, combining world-class diagnostic and drug development capabilities.
Company Financials
EPS
LH has released its 2024 Q4 earnings. EPS was reported at 3.45, versus the expected 3.39, beating expectations. The chart below visualizes how LH has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
LH has released its 2024 Q4 earnings report, with revenue of 3.33B, reflecting a YoY change of 9.76%, and net profit of 143.60M, showing a YoY change of 186.09%. The Sankey diagram below clearly presents LH’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
